Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
Anifrolumab has recently been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of systemic lupus erythematosus (SLE). To be eligible for PBS subsidy, patients must be receiving hydroxychloroquine, an immunosuppressant, and a…
Read more
A novel therapy for the treatment of acne vulgaris is now available. Clascoterone is a topical androgen receptor inhibitor indicated for use in people aged 12 years and older. Androgens stimulate sebum production and…
Read more
Secukinumab is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of moderate to severe hidradenitis suppurativa. Hidradenitis suppurativa is a chronic inflammatory condition of the skin characterised by painful nodules, abscesses,…
Read more
The Therapeutic Goods Administration (TGA) has issued a safety update for selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). The product information for these medicines previously contained warnings of the…
Read more
Tafamidis is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM). This condition is associated with the accumulation of misfolded transthyretin in the myocardium,…
Read more
Mavacamten is now available on the Pharmaceutical Benefits Scheme (PBS) to treat symptomatic obstructive hypertrophic cardiomyopathy. Mavacamten is a novel drug that acts as a selective and reversible inhibitor of cardiac myosin. It reduces…
Read more
